Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen mRNA Vaccine + Adebrelimab + mFOLFIRINOX in Resected Pancreatic Cancer
NCT06156267Phase 1Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jan 2024
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose / Maximum Administered Dose up to 36 months and 2 more. Planned start Jan 2024; status: not yet recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06156267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156267.